Catalent Inc at Barclays Global Healthcare Conference Transcript
Everybody. Luke Sergott here at Barclays to cover Life Sciences Tools and Diagnostics. With me, I have Paul Surdez, VP, Investor Relations; and Tom Castellano, CFO of Catalent. So we're already 45 seconds behind schedule, so I guess we could jump right into the questions here.
Questions & Answers
You made a comment on the last quarter, where you were talking about revisiting your rev rec policy and how that's going to impact the rest of the business. Talk about really the genesis of that comment, and how the business has changed and why you would need to reconsider?
Yes, sure. So thanks, everyone, for having me, Luke, here, and I appreciate the question.
So the question around revenue recognition was really tied specifically to the relationship that Catalent has with Sarepta and their
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |